We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

40 hedge funds and large institutions have $3.85M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

18% less funds holding

Funds holding: 49 → 40 (-9)

42% less capital invested

Capital invested by funds: $6.65M → $3.85M (-$2.8M)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

90% less call options, than puts

Call options by funds: $6K | Put options by funds: $60K

Holders
40
Holders Change
-9
Holders Change %
-18.37%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
9
Reduced
7
Closed
8
Calls
$6K
Puts
$60K
Net Calls
-$54K
Net Calls Change
+$135K

Top Buyers

1
BlackRock
BlackRock
New York
+$605K
2
SM
Sabby Management
Florida
+$409K
3
Renaissance Technologies
Renaissance Technologies
New York
+$188K
4
VKH
Virtu KCG Holdings
New York
+$70.9K
5
ARTA
A.R.T. Advisors
New York
+$48.2K

Top Sellers

1
KCM
Knoll Capital Management
Florida
-$306K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$88K
3
BIC
Beach Investment Counsel
Pennsylvania
-$66K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$41K
5
TSS
Two Sigma Securities
New York
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.25M +$409K +882 +31%
Vanguard Group
2
Vanguard Group
Pennsylvania
$670K +$27.3K +59 +3%
BlackRock
3
BlackRock
New York
$435K +$605K +1,306 New
B
4
Bailard
California
$373K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$191K +$188K +406 +242%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$127K +$463 +1 +0.3%
VKH
7
Virtu KCG Holdings
New York
$83K +$70.9K +153 +156%
UCFA
8
United Capital Financial Advisors
Texas
$72K – – –
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$65K – – –
GBA
10
Garrison Bradford & Associates
New York
$63K – – –
LCM
11
Leisure Capital Management
California
$56K -$2.32K -5 -3%
SIP
12
Stoneridge Investment Partners
Pennsylvania
$46K -$24.6K -53 -27%
Northern Trust
13
Northern Trust
Illinois
$46K +$12.5K +27 +24%
Neuberger Berman Group
14
Neuberger Berman Group
New York
$38K – – –
CCB
15
Cutter & Co Brokerage
Missouri
$37K -$1.85K -4 -3%
New York State Common Retirement Fund
16
New York State Common Retirement Fund
New York
$34K – – –
ARTA
17
A.R.T. Advisors
New York
$34K +$48.2K +104 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$30K +$3.24K +7 +8%
HighTower Advisors
19
HighTower Advisors
Illinois
$24K – – –
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$22K – – –
FNBT
21
FineMark National Bank & Trust
Florida
$19K – – –
PNC Financial Services Group
22
PNC Financial Services Group
Pennsylvania
$17K – – –
WMC
23
Westwood Management Corporation
Illinois
$17K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$16K – – –
UBS Group
25
UBS Group
Switzerland
$10K -$5.56K -12 -29%
1
2

NBSE Hedge Fund Activity: Q1 2017 in Review

40 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2017, worth a combined $3.85M — down 42% from $6.65M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of NBSE and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was BlackRock, opening a new position worth an estimated $605K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $306K sold.

  • 40 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2017, down from 49 in Q4 2016.
  • Funds reported $3.85M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2017, down 42% quarter-over-quarter.
  • 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2017 and 8 closed out, a net change of -5 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $605K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2017 was Knoll Capital Management, an estimated $306K sold.

Based on aggregated 13F filings for Q1 2017.